Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Dopamine Precursor / Decarboxylase Inhibitor Pregnancy: §4.6 verbatim: 'Although the effects of Sinemet on human pregnancy are unknown, both levodopa and combinations of carbidopa and levodopa have caused visceral and skeletal malformations in rabbits. Therefore, the use of Sinemet in women of childbearing potential requires that the anticipated benefits of the drug be weighed against possible hazards should pregnancy occur.' Breast-feeding: 'It is not known whether carbidopa is excreted in human milk. In a study of one nursing mother with Parkinson's disease, excretion of levodopa in human breast milk was reported... a decision should be made whether to discontinue breast-feeding or discontinue the use of Sinemet, taking into account the importance of the drug to the mother.'

Levodopa-Carbidopa (Co-Careldopa)

Brand names: Sinemet, Caramet, Duodopa (enteral)

Co-careldopa (levodopa with carbidopa) is the mainstay treatment of Parkinson's disease, replacing dopamine; carbidopa reduces peripheral side effects.

Adult dose

Dose: Parkinson's disease — STANDARD (immediate-release) oral Sinemet tablets. §4.1 verbatim: 'For the treatment of Parkinson's disease and syndrome.' PATIENTS NOT ALREADY ON LEVODOPA, §4.2 verbatim: 'Dosage may be best initiated with one tablet of Sinemet Plus 25 mg/100 mg three times a day. This dosage schedule provides 75 mg of carbidopa per day.' — or, 'If Sinemet 10 mg/100 mg Tablets or Sinemet 12.5 mg/50 mg Tablets are used, dosage may be initiated with one tablet three or four times a day.' Titration: 'Dosage may be increased by one tablet of Sinemet 12.5 mg/50 mg or Sinemet Plus 25 mg/100 mg every day or every other day, as necessary, until a dosage equivalent of eight tablets of Sinemet Plus 25 mg/100 mg a day is reached.' PATIENTS TRANSFERRING FROM LEVODOPA ALONE: 'Discontinue levodopa at least 12 hours (24 hours for slow-release preparations) before starting therapy with Sinemet... The dose of Sinemet should be approximately 20% of the previous daily dosage of levodopa. Patients taking less than 1,500 mg levodopa a day should be started on one tablet of Sinemet Plus 25 mg/100 mg three or four times a day dependent on patient need. The suggested starting dose for most patients taking more than 1,500 mg levodopa a day is one tablet of Sinemet 25 mg/250 mg three or four times a day.' MAINTENANCE: 'When more levodopa is required, Sinemet 25 mg/250 mg Tablets should be substituted at a dosage of one tablet three or four times a day.' SCOPE — this source covers the STANDARD-RELEASE oral tablet range only (Sinemet 10 mg/100 mg, 12.5 mg/50 mg, Plus 25 mg/100 mg, 25 mg/250 mg). It does NOT cover prolonged-release Sinemet CR / Half Sinemet CR, and it does NOT cover Duodopa intestinal gel, which is a different route entirely; those need their own SPCs.
Route: Oral. §4.2 verbatim: 'For oral use. If a tablet breaks when it is removed from the packaging, it should only be consumed if the whole dose can be taken. If it cannot, the pieces of the broken tablet should be discarded and another tablet taken from the packaging. Administration of a partial dose may result in worsening of symptoms.'
Frequency: Three or four times a day (see the dose text — the number of daily tablets is what is titrated, not the interval)
Max: The label states the ceiling as a TABLET COUNT, not a milligram total. For patients started on Sinemet Plus 25 mg/100 mg, Sinemet 12.5 mg/50 mg or Sinemet 10 mg/100 mg, §4.2: increase 'until a dosage equivalent of eight tablets of Sinemet Plus 25 mg/100 mg a day is reached', and for the 10 mg/100 mg and 12.5 mg/50 mg tablets 'until a total of eight tablets (two tablets q.d.s.) is reached'. For Sinemet 25 mg/250 mg: 'the dosage of Sinemet 25 mg/250 mg Tablets may be increased by one tablet every day or every other day to a maximum of eight tablets a day.' §4.2 adds the carbidopa limit verbatim: 'Experience with a total daily dosage greater than 200 mg carbidopa is limited.' No milligram ceiling for levodopa is stated in this label — do not quote one.
Titration principle, §4.2 verbatim: 'The optimum daily dosage of Sinemet must be determined by careful titration in each patient.' Carbidopa saturation: 'Studies show that the peripheral dopa-decarboxylase is fully inhibited (saturated) by carbidopa at doses between 70 and 100 mg a day. Patients receiving less than this amount of carbidopa are more likely to experience nausea and vomiting.' Onset: 'Response has been observed in one day, and sometimes after one dose. Fully effective doses usually are reached within seven days as compared to weeks or months with levodopa alone.' Overdose signal: 'Involuntary movements, particularly blepharospasm, are a useful early sign of excess dosage in some patients.' Transfer from another decarboxylase inhibitor: 'discontinue dosage at least 12 hours before Sinemet is started. Begin with a dosage of Sinemet that will provide the same amount of levodopa as contained in the other levodopa/decarboxylase inhibitor combination.' Withdrawal: §4.4 warns that 'A syndrome resembling the neuroleptic malignant syndrome... has been reported with the abrupt withdrawal of antiparkinsonian agents.' Anaesthesia, §4.4: 'If general anaesthesia is required, therapy with Sinemet may be continued for as long as the patient is permitted to take fluids and medication by mouth.'

Paediatric dose

Route: Not applicable — not recommended below 18 years of age
Max: Not established
UK SPC §4.2 'Paediatric population', verbatim: 'The safety and efficacy of Sinemet in children under 18 years of age has not been established and its use in patients below the age of 18 is not recommended.' No paediatric dose is published here. Any off-label paediatric use (for example in dopamine-responsive dystonia) must be checked against a children's formulary and specialist paediatric neurology advice.

Dose adjustments

Renal

No renal dose adjustment is stated in §4.2 of this SPC. §4.4 advises caution in renal disease and that 'periodic evaluation of hepatic, haematopoetic, cardiovascular and renal function are recommended during extended therapy.'

Hepatic

No hepatic dose adjustment is stated in §4.2 of this SPC. §4.4 advises that Sinemet 'should be administered cautiously to patients with... renal, hepatic or endocrine disease'.

Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via the eMC — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.

Contraindications

  • Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1
  • Non-selective monoamine oxidase (MAO) inhibitors — §4.3: 'These inhibitors must be discontinued at least two weeks before starting Sinemet.' (Sinemet may be given with a manufacturer's recommended dose of a MAO-B-selective inhibitor such as selegiline hydrochloride.)
  • Narrow-angle glaucoma
  • Suspicious undiagnosed skin lesions or a history of melanoma — §4.3: 'Since levodopa may activate a malignant melanoma, it should not be used in patients with suspicious undiagnosed skin lesions or a history of melanoma.'
  • Use in patients with severe psychoses

Side effects

  • Most common (§4.8): 'dyskinesias including choreiform, dystonic and other involuntary movements and nausea' — 'These reactions can usually be diminished by dosage reduction.'
  • Early signs of excess dose: muscle twitching and blepharospasm
  • Very common: urinary tract infections
  • Nervous system / psychiatric: bradykinetic episodes (the 'on-off' phenomenon), dizziness, paraesthesia, psychotic episodes including delusions, hallucinations and paranoid ideation, depression with or without development of suicidal tendencies, dementia, dream abnormalities, agitation, confusion, increased libido
  • Somnolence — 'Levodopa is associated with somnolence and has been associated very rarely with excessive daytime somnolence and sudden sleep onset episodes.'
  • Neuroleptic malignant syndrome
  • Cardiovascular: cardiac irregularities and/or palpitations, orthostatic effects including hypotensive episodes, hypertension, phlebitis
  • Gastrointestinal: vomiting, gastro-intestinal bleeding, development of duodenal ulcer, diarrhoea, dark saliva
  • Haematological: leucopenia, haemolytic and non-haemolytic anaemia, thrombocytopenia, agranulocytosis
  • Hypersensitivity: angioedema, urticaria, pruritus, Henoch-Schonlein purpura
  • Dopamine Dysregulation Syndrome (DDS) — 'an addictive disorder seen in some patients treated with carbidopa/levodopa. Affected patients show a compulsive pattern of dopaminergic drug misuse above doses adequate to control motor symptoms, which may in some cases result in severe dyskinesias.'
  • Impulse control disorders: 'Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating'
  • Other: syncope, chest pain, anorexia, dyspnoea, alopecia, rash, dark sweat, dark urine; rarely convulsions ('a causal relationship with Sinemet has not been established')
  • This side-effect list may be incomplete — check the full SPC.

Monitoring

  • Driving/sleep — §4.4: 'Levodopa has been associated with somnolence and episodes of sudden sleep onset... Patients must be informed of this and advised to exercise caution while driving or operating machines during treatment with levodopa. Patients who have experienced somnolence and/or an episode of sudden sleep onset must refrain from driving or operating machines.'
  • Mental state — §4.4: 'All patients should be monitored carefully for the development of mental changes, depression with suicidal tendencies, and other serious antisocial behaviour.'
  • Impulse control disorders — §4.4: 'Patients should be regularly monitored for the development of impulse control disorders... Review of treatment is recommended if such symptoms develop.'
  • Dopamine Dysregulation Syndrome — §4.4: 'Before initiation of treatment, patients and caregivers should be warned of the potential risk of developing DDS.'
  • Melanoma — §4.4: 'patients and providers are advised to monitor for melanomas on a regular basis when using Sinemet for any indication. Ideally, periodic skin examinations should be performed by appropriately qualified individuals (e.g., dermatologists).'
  • Extended therapy — §4.4: 'As with levodopa, periodic evaluation of hepatic, haematopoetic, cardiovascular and renal function are recommended during extended therapy.'
  • Cardiac — §4.4: in patients with a history of myocardial infarction and residual arrhythmias, 'Cardiac function should be monitored with particular care in such patients during the period of initial dosage adjustment.'
  • Glaucoma — §4.4: 'Patients with chronic wide-angle glaucoma may be treated cautiously with Sinemet, provided the intra-ocular pressure is well controlled and the patient monitored carefully for changes in intra-ocular pressure during therapy.'
  • Laboratory interference — §4.4: 'Sinemet may cause a false positive result when a dipstick is used to test for urinary ketone... The use of glucose oxidase methods may give false negative results for glycosuria.'
  • §4.4/§4.5 are TRUNCATED in this bundle (they break off in the antidepressant interaction paragraph) — this is not the label's complete set of precautions or interactions

Clinical monograph

How it works

Levodopa is converted to dopamine in the brain; carbidopa, a peripheral dopa-decarboxylase inhibitor that does not cross the blood-brain barrier, reduces peripheral conversion (and so nausea) and allows lower levodopa doses.

Prescribing in practice

  • It is the most effective symptomatic therapy, but long-term use is limited by motor fluctuations ('wearing off') and dyskinesias.
  • Do not stop it abruptly — sudden withdrawal can cause a neuroleptic-malignant-like syndrome; timing relative to protein-rich meals affects absorption.
  • Nausea, postural hypotension, hallucinations and impulse-control disorders can occur.

Monitoring

Review motor response and fluctuations, blood pressure, and neuropsychiatric effects (hallucinations, impulse control).

Counselling the patient

  • Take it at regular times as directed; do not stop it suddenly.
  • Separating doses from high-protein meals can help if it seems less effective.
  • Report new compulsive behaviours (gambling, shopping) or hallucinations.

Evidence & guidelines

The most effective symptomatic treatment for Parkinson's disease (NICE NG71), with long-term motor complications to manage.

Reference: NICE NG71 Parkinson's Disease; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways